Recent Investment Analysts’ Ratings Changes for Galecto (GLTO)

Several brokerages have updated their recommendations and price targets on shares of Galecto (NASDAQ: GLTO) in the last few weeks:

• 12/1/2025 – Galecto had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Galecto is now covered by analysts at Guggenheim. They set a “buy” rating and a $32.00 price target on the stock.
• 12/1/2025 – Galecto is now covered by analysts at Guggenheim. They set a “buy” rating and a $32.00 price target on the stock.
• 11/24/2025 – Galecto had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Galecto was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/17/2025 – Galecto had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/16/2025 – Galecto was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/8/2025 – Galecto was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/5/2025 – Galecto had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/25/2025 – Galecto was upgraded by analysts at Wall Street Zen to a “sell” rating.
• 10/14/2025 – Galecto had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.